# A Study of Replagal in Treatment-naïve Adults With Fabry Disease

> **NCT04840667** · PHASE3 · TERMINATED · sponsor: **Shire** · enrollment: 17 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** REPLAGAL

## Key facts

- **NCT ID:** NCT04840667
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-28
- **Primary completion:** 2022-12-16
- **Final completion:** 2022-12-16
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Study closed due to enrolment challenges, not for any safety issues
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04840667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04840667, "A Study of Replagal in Treatment-naïve Adults With Fabry Disease". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04840667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*